Abstract
Ginsenosides, which are active compounds found in ginseng (Panax ginseng), are used as antidiabetic treatments. The aim of this study was to determine whether Rb2, a type of ginsenoside, regulates hepatic gluconeogenesis through AMP-activated protein kinase (AMPK) and the orphan nuclear receptor small heterodimer partner (SHP) in hyperlipidemic conditions used as an in vitro model of type 2 diabetes. Considering these results, we concluded that Rb2 may inhibit palmitate-induced gluconeogenesis via AMPK-induced SHP by relieving ER stress, a cause of gluconeogenesis.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
AMP-Activated Protein Kinases / metabolism*
-
Animals
-
Diabetes Mellitus, Type 2 / drug therapy
-
Gene Silencing / drug effects
-
Ginsenosides / metabolism
-
Ginsenosides / pharmacology*
-
Gluconeogenesis / drug effects
-
Glucose / analysis
-
Glucose / biosynthesis
-
Hepatocytes / drug effects
-
Hypoglycemic Agents / metabolism
-
Hypoglycemic Agents / pharmacology*
-
Liver / drug effects
-
Liver / metabolism
-
Phosphorylation / drug effects*
-
Protein Tyrosine Phosphatase, Non-Receptor Type 6 / drug effects
-
RNA / analysis
-
Rats
-
Transfection
Substances
-
Ginsenosides
-
Hypoglycemic Agents
-
ginsenoside Rb2
-
RNA
-
AMP-Activated Protein Kinases
-
Protein Tyrosine Phosphatase, Non-Receptor Type 6
-
Ptpn6 protein, rat
-
Glucose